instil bio is a cell therapy company developing tumor infiltrating lymphocytes (til) for the treatment of solid tumor cancers. til are a patient’s own t cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. the company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered til. the company is led by world-class cell therapy experts and backed by premier global institutional investors. instil is located in the greater los angeles area with additional manufacturing and research facilities in manchester, uk.
Company profile
Ticker
TIL
Exchange
Website
CEO
Bronson Crouch
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Instil Bio (UK) Limited • Cellular Therapeutics Limited • Complex Therapeutics Mezzanine LLC • Complex Therapeutics LLC ...
TIL stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
8-K
Departure of Directors or Certain Officers
14 Feb 24
8-K
Other Events
18 Jan 24
8-K
Instil Bio Announces Strategic Update
16 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Dec 23
8-K
Regulation FD Disclosure
27 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
Latest ownership filings
SC 13G
BML Investment Partners, L.P.
2 Apr 24
4
Sandeep Laumas
13 Feb 24
4
Bronson Crouch
13 Feb 24
4
Gwendolyn Binder
10 Jan 24
4
R Kent McGaughy Jr
10 Jan 24
4
Neil W Gibson
10 Jan 24
4
George Matcham
10 Jan 24
4
Jack Nielsen
10 Jan 24
SC 13G/A
FMR LLC
10 Apr 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.15 mm | 10.15 mm | 10.15 mm | 10.15 mm | 10.15 mm | 10.15 mm |
Cash burn (monthly) | 4.26 mm | 2.62 mm | 22.48 mm | 16.97 mm | 4.81 mm | 8.80 mm |
Cash used (since last report) | 28.37 mm | 17.46 mm | 149.68 mm | 113.02 mm | 32.02 mm | 58.61 mm |
Cash remaining | -18.22 mm | -7.32 mm | -139.54 mm | -102.87 mm | -21.88 mm | -48.47 mm |
Runway (months of cash) | -4.3 | -2.8 | -6.2 | -6.1 | -4.5 | -5.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 63 |
Opened positions | 14 |
Closed positions | 23 |
Increased positions | 7 |
Reduced positions | 25 |
13F shares | Current |
---|---|
Total value | 44.66 bn |
Total shares | 101.47 mm |
Total puts | 1.40 k |
Total calls | 11.50 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Curative Ventures V | 37.98 mm | $20.93 bn |
Vivo Capital | 12.49 mm | $6.88 bn |
Vivo Capital IX | 12.49 mm | $327.15 mm |
CPMG | 8.22 mm | $4.53 bn |
Venrock Healthcare Capital Partners II | 6.87 mm | $179.87 mm |
Baker Bros. Advisors | 5.27 mm | $2.91 bn |
Vanguard | 2.70 mm | $1.49 bn |
Millennium Management | 1.82 mm | $1.01 bn |
Western Standard | 1.80 mm | $990.14 mm |
Samsara BioCapital | 1.79 mm | $985.34 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Feb 24 | Laumas Sandeep | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 11.6 | 80,000 | 928.00 k | 80,000 |
10 Feb 24 | Bronson Crouch | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 11.6 | 120,000 | 1.39 mm | 120,000 |
14 Jun 23 | Nielsen Jack | Stock Option Common Stock | Grant | Acquire A | No | No | 11.18 | 1,500 | 16.77 k | 1,500 |
14 Jun 23 | George Matcham | Stock Option Common Stock | Grant | Acquire A | No | No | 11.18 | 1,500 | 16.77 k | 1,500 |
14 Jun 23 | Gibson Neil W | Stock Option Common Stock | Grant | Acquire A | No | No | 11.18 | 1,500 | 16.77 k | 1,500 |
News
Jefferies Downgrades Instil Bio to Hold, Raises Price Target to $11
12 Apr 24
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $18 Price Target
25 Mar 24
Instil Bio Q4 Adj EPS $(1.26) Beats $(2.85) Estimate
21 Mar 24
HC Wainwright & Co. Maintains Buy on Instil Bio, Adjusts Price Target To $18
22 Jan 24